High Triglyceridemia - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
104 Pages - GMD12039
$2,000.00

Summary

Global Markets Direct’s, ‘High Triglyceridemia - Pipeline Review, H1 2014’, provides an overview of the High Triglyceridemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of High Triglyceridemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for High Triglyceridemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the High Triglyceridemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the High Triglyceridemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
High Triglyceridemia Overview 8
Therapeutics Development 9
Pipeline Products for High Triglyceridemia - Overview 9
Pipeline Products for High Triglyceridemia - Comparative Analysis 10
High Triglyceridemia - Therapeutics under Development by Companies 11
High Triglyceridemia - Therapeutics under Investigation by Universities/Institutes 13
High Triglyceridemia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
High Triglyceridemia - Products under Development by Companies 17
High Triglyceridemia - Products under Investigation by Universities/Institutes 18
High Triglyceridemia - Companies Involved in Therapeutics Development 19
Tekmira Pharmaceuticals Corp. 19
Actavis plc 20
Isis Pharmaceuticals, Inc. 21
Novartis AG 22
Astellas Pharma Inc. 23
Amarin Corporation plc 24
Alnylam Pharmaceuticals, Inc. 25
Catabasis Pharmaceuticals, Inc. 26
Cardax Pharmaceuticals, Inc. 27
Essentialis, Inc. 28
Epax AS 29
Pharmena SA 30
FORMAC Pharmaceuticals N.V. 31
Omthera Pharmaceuticals, Inc. 32
Poxel SA 33
Acasti Pharma Inc. 34
High Triglyceridemia - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 39
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
icosapent ethyl - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
omega-3-carboxylic acids - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
diazoxide CR - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AKR-963 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TRIA-662 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ISIS-APOCIIIRx - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
NKPL-66 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
pradigastat sodium - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CAT-2003 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
fenofibrate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
bezafibrate ER - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CDX-085 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CAT-2000 Series - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AS-1708727 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MAT-9001 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Drug For Hypertriglyceridemia - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ALN-ANG - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecule Farnesoid X Receptor Agonist for Gastrointestinal, Metabolic and Cardiovascular Diseases - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
High Triglyceridemia - Recent Pipeline Updates 71
High Triglyceridemia - Dormant Projects 96
High Triglyceridemia - Discontinued Products 97
High Triglyceridemia - Product Development Milestones 98
Featured News & Press Releases 98
Jan 21, 2014: Amarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request 98
Jan 15, 2014: Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement Reinstatement Request Will Be Delayed 99
Dec 20, 2013: Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed 99
Dec 05, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia 100
Nov 11, 2013: Acasti Completes PK IND Submission 100
Oct 22, 2013: Amarin Announces Plans to Reduce Expenses by Decreasing Staff Following Recent FDA Advisory Committee Vote 101
Oct 16, 2013: FDA Advisory Committee to Review sNDA for Vascepa ANCHOR Indication 101
Oct 09, 2013: Amarin to Host Conference Call on October 16, 2013 to Discuss Results of FDA Advisory Committee Meeting on ANCHOR Supplemental New Drug Application for Vascepa 101
Oct 03, 2013: Amarin Informed by FDA That October 16th Advisory Committee Meeting Will Take Place as Scheduled 102
Sep 25, 2013: Amarin Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients 102
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Tables
Number of Products under Development for High Triglyceridemia, H1 2014 9
Number of Products under Development for High Triglyceridemia - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
High Triglyceridemia - Pipeline by Tekmira Pharmaceuticals Corp., H1 2014 19
High Triglyceridemia - Pipeline by Actavis plc, H1 2014 20
High Triglyceridemia - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 21
High Triglyceridemia - Pipeline by Novartis AG, H1 2014 22
High Triglyceridemia - Pipeline by Astellas Pharma Inc., H1 2014 23
High Triglyceridemia - Pipeline by Amarin Corporation plc, H1 2014 24
High Triglyceridemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 25
High Triglyceridemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 26
High Triglyceridemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2014 27
High Triglyceridemia - Pipeline by Essentialis, Inc., H1 2014 28
High Triglyceridemia - Pipeline by Epax AS, H1 2014 29
High Triglyceridemia - Pipeline by Pharmena SA, H1 2014 30
High Triglyceridemia - Pipeline by FORMAC Pharmaceuticals N.V., H1 2014 31
High Triglyceridemia - Pipeline by Omthera Pharmaceuticals, Inc., H1 2014 32
High Triglyceridemia - Pipeline by Poxel SA, H1 2014 33
High Triglyceridemia - Pipeline by Acasti Pharma Inc., H1 2014 34
Assessment by Monotherapy Products, H1 2014 35
Number of Products by Stage and Target, H1 2014 38
Number of Products by Stage and Mechanism of Action, H1 2014 41
Number of Products by Stage and Route of Administration, H1 2014 43
Number of Products by Stage and Molecule Type, H1 2014 45
High Triglyceridemia Therapeutics - Recent Pipeline Updates, H1 2014 71
High Triglyceridemia - Dormant Projects, H1 2014 96
High Triglyceridemia - Discontinued Products, H1 2014 97

List of Figures
Number of Products under Development for High Triglyceridemia, H1 2014 9
Number of Products under Development for High Triglyceridemia - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 35
Number of Products by Top 10 Target, H1 2014 36
Number of Products by Stage and Top 10 Target, H1 2014 37
Number of Products by Top 10 Mechanism of Action, H1 2014 39
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 40
Number of Products by Top 10 Route of Administration, H1 2014 42
Number of Products by Stage and Top 10 Route of Administration, H1 2014 43
Number of Products by Top 10 Molecule Type, H1 2014 44
Number of Products by Stage and Top 10 Molecule Type, H1 2014 45

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax